Premium
Cardiac 18 F‐Dopamine PET Distinguishes PD with Orthostatic Hypotension from Parkinsonian MSA
Author(s) -
Lenka Abhishek,
Lamotte Guillaume,
Goldstein David S.
Publication year - 2021
Publication title -
movement disorders clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 18
ISSN - 2330-1619
DOI - 10.1002/mdc3.13190
Subject(s) - dopamine , positron emission tomography , orthostatic vital signs , medicine , parkinson's disease , nuclear medicine , cardiology , endocrinology , anesthesia , disease , blood pressure
Background Parkinson's disease with orthostatic hypotension (PD + OH) can be difficult to distinguish clinically from the parkinsonian form of multiple system atrophy (MSA‐P). Previous studies examined cardiac sympathetic neuroimaging to differentiate PD from MSA but without focusing specifically on PD + OH versus MSA‐P, which often is the relevant differential diagnostic issue. Objective To investigate the utility of cardiac sympathetic neuroimaging by 18 F‐dopamine positron emission tomographic (PET) scanning for separating PD + OH from MSA‐P. Methods Cardiac 18 F‐dopamine PET data were analyzed from 50 PD + OH and 68 MSA‐P patients evaluated at the NIH Clinical Center from 1990 to 2020. Noradrenergic deficiency was defined by interventricular septal 18 F‐dopamine‐derived radioactivity <6000 nCi‐kg/cc‐mCi in the 5′ frame with mid‐point 8′ after initiation of 3′ tracer injection. Results 18 F‐Dopamine PET separated the PD + OH from the MSA‐P group with a sensitivity of 92% and specificity of 96%. Conclusion Cardiac 18 F‐dopamine PET scanning efficiently distinguishes PD + OH from MSA‐P.